RESUMEN
Butyrolactone I (BTL-I) is a butanolide isolated from the deep-sea-derived fungus, Aspergillus sp. It provides a potential new target for the prevention and treatment of food allergies. This study aimed to investigate the metabolic and pharmacokinetic profile of BTL-I in rats. The metabolic profiles were obtained by UHPLC-Q-TOF-MS. As a result, eleven metabolites were structurally identified, and the proposed metabolic pathways of BTL-I were characterized. The main metabolites were the oxidative and glucuronidative metabolites. In addition, a sensitive UHPLC-MS/MS method was established for the quantitation of BTL-I in rat plasma (LOQ = 2 ng/mL). The method was fully validated and successfully applied to the pharmacokinetic study of BTL-I in rats after oral administration or intravenous administration. The oral bioavailability was calculated as 6.29%, and the maximum plasma concentrations were 9.85 ± 1.54 ng/mL and 17.97 ± 1.36 ng/mL for intravenous and intragastric dosing groups, respectively.
Asunto(s)
4-Butirolactona/análogos & derivados , Antialérgicos/farmacocinética , Aspergillus , 4-Butirolactona/administración & dosificación , 4-Butirolactona/sangre , 4-Butirolactona/farmacocinética , Administración Oral , Animales , Antialérgicos/administración & dosificación , Antialérgicos/sangre , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Hipersensibilidad a los Alimentos/prevención & control , Infusiones Intravenosas , Masculino , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en TándemRESUMEN
This study shows the development and validation of two enantioselective LC-MS/MS methods for the determination of fexofenadine in biological matrices including the elution order determination. Plasma (200 µL) or urine (50 µL) aliquots were added to the internal standard solution [(S)-(-)-metoprolol] and extracted in the acid medium with chloroform. Resolution of the (R)-(+)- and (S)-(-)-fexofenadine enantiomers was performed in a Chirobiotic V column. The methods showed linearity at the range of 0.025-100 ng/mL plasma and 0.02-10 µg/mL urine for each fexofenadine enantiomer. These methods were applied to the maternal-fetal pharmacokinetics of fexofenadine enantiomers in plasma and urine of parturient women (n = 8) treated with a single oral 60 mg dose of racemic fexofenadine. Enantiomeric ratio in plasma (AUC0-∞(R)-(+)/(S)-(-)) was close to 1.5, nevertheless in urine was closed to unity. The transplacental transfer was approximately 18% for both fexofenadine enantiomers. The enantioselective methods can also be useful in future clinical studies of chiral discrimination of drug transporters.
Asunto(s)
Antialérgicos/sangre , Antialérgicos/orina , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Terfenadina/análogos & derivados , Adulto , Antialérgicos/química , Antialérgicos/farmacocinética , Femenino , Humanos , Plasma/química , Embarazo , Estereoisomerismo , Terfenadina/sangre , Terfenadina/química , Terfenadina/farmacocinética , Terfenadina/orina , Orina/química , Adulto JovenRESUMEN
BACKGROUND AND PURPOSE: The 5-lipoxygenase product 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE), acting through the OXE receptor, is a potent eosinophil chemoattractant that may be an important proinflammatory mediator in eosinophilic diseases such as asthma. We previously identified a series of indole-based OXE receptor antagonists that rapidly appear in the blood following oral administration but have limited lifetimes. The objective of this study was to increase the potency and plasma half-lives of these compounds and thereby identify the optimal candidate for future preclinical studies in monkeys, as rodents do not have an OXE receptor orthologue. EXPERIMENTAL APPROACH: We synthesized a series of substituted phenylalkyl indoles and compared their antagonist potencies, pharmacokinetics, and metabolism to those of our earlier compounds. The potencies of some of their metabolites were also investigated. KEY RESULTS: Among the compounds tested, the S-enantiomer of the m-chlorophenyl compound (S-Y048) was the most potent, with an pIC50 of about 10.8 for inhibition of 5-oxo-ETE-induced calcium mobilization in human neutrophils. When administered orally to cynomolgus monkeys, S-Y048 rapidly appeared in the blood and had a half-life in plasma of over 7 hr, considerably longer than any of the other OXE analogues tested. A major hydroxylated metabolite, with a potency close to that of its precursor, was identified in plasma. CONCLUSION AND IMPLICATIONS: Because of its highly potent antagonist activity and its long lifetime in vivo, S-Y048 may be a useful anti-inflammatory agent for the treatment of eosinophilic diseases such as asthma, allergic rhinitis, and atopic dermatitis.
Asunto(s)
Antialérgicos/farmacocinética , Antiinflamatorios/farmacocinética , Indoles/farmacocinética , Neutrófilos/efectos de los fármacos , Receptores Eicosanoides/antagonistas & inhibidores , Activación Metabólica , Administración Oral , Animales , Antialérgicos/sangre , Antialérgicos/síntesis química , Antiinflamatorios/sangre , Antiinflamatorios/síntesis química , Calcio/metabolismo , Femenino , Semivida , Humanos , Hidroxilación , Indoles/sangre , Indoles/síntesis química , Macaca fascicularis , Neutrófilos/metabolismo , Receptores Eicosanoides/metabolismo , Relación Estructura-ActividadRESUMEN
BACKGROUND: Allergic diseases are considered as the major burden on public health with increased prevalence globally. Histamine H1-receptor antagonists are the foremost commonly used drugs in the treatment of allergic disorders. The target drug in this study, loratadine, belongs to this class of drugs and its biometabolite desloratadine which is also a non-sedating H1 receptor antagonist with anti-histaminic activity being 2.5 to 4 times greater than loratadine. This study aimed to develop and validate a novel isocratic Reversed-phase High-Performance Liquid Chromatography (RP-HPLC) method for rapid and simultaneous separation and determination of loratadine and its metabolite, desloratadine in human plasma. METHODS: The drug extraction method from plasma was based on protein precipitation technique. The separation was carried out on a Thermo Scientific BDS Hypersil C18 column (5µm, 250 x 4.60 mm) in a mobile phase of MeOH: 0.025M KH2PO4 adjusted to pH 3.50 using orthophosphoric acid (85: 15, v/v) at an ambient temperature. The flow rate was maintained at 1 mL/min and maximum absorption was measured using the PDA detector at 248 nm. RESULTS: The retention times of loratadine and desloratadine in plasma samples were recorded to be 4.10 and 5.08 minutes, respectively, indicating a short analysis time. Limits of detection were found to be 1.80 and 1.97 ng/mL for loratadine and desloratadine, respectively, showing a high degree of sensitivity of the method. The method was then validated according to FDA guidelines for the determination of the two analytes in human plasma. CONCLUSION: The results obtained indicate that the proposed method is rapid, sensitive in the nanogram range, accurate, selective, robust and reproducible compared to other reported methods.
Asunto(s)
Antialérgicos/sangre , Loratadina/análogos & derivados , Cromatografía Líquida de Alta Presión , Humanos , Loratadina/sangre , Reproducibilidad de los ResultadosRESUMEN
INTRODUCTION: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody, approved for patients affected by chronic spontaneous urticaria resistant to antihistamines. Although the clinical benefit of omalizumab has been established in several clinical trials, there are very little data about long-term treatment with this drug and real-life reports regarding its use in patients affected by comorbidities other than urticaria are lacking. OBJECTIVES: To assess omalizumab efficacy and safety in a heterogeneous population of patients affected by chronic spontaneous urticaria and several comorbidities in a real-world setting. MATERIALS AND METHODS: Patients affected by chronic spontaneous urticaria with weekly urticaria activity score >16 resistant to antihistamines were treated with omalizumab 300 mg injection as add-on to H1-antihistamines administered every 4 weeks for 6 months. Clinical assessment of weekly urticaria activity score, dermatology life quality index and blood tests were performed at baseline, 12, 24 and 52 weeks of treatment. Response was assessed based on reduction weekly urticaria activity score. RESULTS: Thirty-two patients (22F; 10M) with a mean age of 52.4 years (range 27-72) affected by chronic spontaneous urticaria were enrolled. Comorbidities affecting our study population were divided into 6 categories: cardio-metabolic (77%), oncologic (19%), infectious (16%), allergic (45%) immunologic (41%) and others (18%). Omalizumab determined a satisfactory reduction of symptoms of chronic spontaneous urticaria and an amelioration of quality of life within our population. No relevant alterations regarding patients' underlying conditions were encountered. This is the first study regarding the use of omalizumab for chronic spontaneous urticaria in a population of adult patients affected by several comorbidities, eg, cardio-metabolic, oncologic, infectious, allergic, immunologic and psychiatric diseases. Real-life data represent a valuable source of information about a drug's safety and efficacy profile, especially in patients affected by different comorbidities that are widely diffused in Western countries.
Asunto(s)
Antialérgicos/uso terapéutico , Urticaria Crónica/tratamiento farmacológico , Omalizumab/uso terapéutico , Adulto , Anciano , Antialérgicos/administración & dosificación , Antialérgicos/sangre , Femenino , Humanos , Inyecciones Subcutáneas , Italia , Masculino , Persona de Mediana Edad , Omalizumab/administración & dosificación , Omalizumab/sangre , Calidad de Vida , Estudios RetrospectivosRESUMEN
Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy. This study investigated the pharmacokinetics (PK) of fexofenadine (P-glycoprotein substrate) following single- and multiple-dose osimertinib in patients with advanced NSCLC who have progressed on prior EGFR-TKI therapy. This open-label, phase 1 study (NCT02908750) comprised the PK phase and continued access phase. The former comprised 2 distinct periods with a 3- to 7-day washout: treatment period 1 (n = 24, fexofenadine 120 mg, day 1) and treatment period 2 (fexofenadine 120 mg + osimertinib 80 mg single dose on days 1 and 39 and osimertinib 80 mg once daily from days 4 to 41). Patients could continue osimertinib 80 mg once daily based on investigator's discretion in the continued access phase. Fexofenadine area under the plasma concentration-time curve and maximum concentration increased by 56% (90% confidence interval [CI], 35.4-78.6) and 76% (90%CI, 49.3-108.3) following coadministration with osimertinib single dose, and by 27% (90%CI, 11.2-45.8) and 25% (90%CI, 5.6-48.1) when given with osimertinib at steady state, respectively. Following osimertinib coadministration, median fexofenadine time to maximum concentration increased by approximately 30 minutes compared with time to maximum concentration following fexofenadine alone. No new osimertinib safety findings were observed. The increase in fexofenadine exposure following osimertinib coadministration shows osimertinib as a weak P-glycoprotein inhibitor.
Asunto(s)
Acrilamidas/farmacología , Compuestos de Anilina/farmacología , Antialérgicos/farmacocinética , Antineoplásicos/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Terfenadina/análogos & derivados , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Anciano , Antialérgicos/sangre , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/embriología , Carcinoma de Pulmón de Células no Pequeñas/genética , Interacciones Farmacológicas , Receptores ErbB/genética , Femenino , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Masculino , Persona de Mediana Edad , Mutación , Terfenadina/sangre , Terfenadina/farmacocinéticaRESUMEN
Thirty-two Collies were used to determine the impact of ABCB1 genotype and phenotype on the plasma pharmacokinetics of fexofenadine's (Fex) R- and S-enantiomers after bolus Fex administration, as human P-gp exhibits stereoselectivity. Each Collie's ABCB1 genotype and ivermectin (IVM) sensitivity (phenotype) was determined prior to study enrolment. Wild-type (WT) Collies had lower plasma concentrations of the individual enantiomers as compared to heterozygous IVM nonsensitive (HNS), heterozygous IVM-sensitive (HS) and homozygous mutant (MUT) Collies. Based on pairwise statistical comparison, WT Collies had statistically significantly lower (AUC0-last ) and peak (Cmax ) values compared to HS, HNS and MUT Collies. Tmax was not influenced by genotype/phenotype. Inter-individual variability in PK metrics tended to be largest for WT Collies. Although the influence of genotype/phenotype on Fex PK occurred with the individual isomers, impairment of S-Fex absorption, particularly in the MUT dogs, exceeded that associated with R-Fex. Since Fex elimination occurs primarily via biliary excretion via a transporter other than P-glycoprotein, and based upon our understanding of Fex absorption kinetics, we attributed these differences primarily to the absorption portion of the profile. These differences are expressed in a stereo-specific manner. These results demonstrate the potential negative impact on estimates of drug effectiveness and toxicity, especially for P-gp substrates that do not exhibit Central Nervous System toxicities.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Antialérgicos/farmacocinética , Perros/genética , Genotipo , Terfenadina/análogos & derivados , Animales , Antialérgicos/sangre , Área Bajo la Curva , Perros/metabolismo , Femenino , Semivida , Masculino , Terfenadina/sangre , Terfenadina/farmacocinéticaRESUMEN
AIMS: To optimise a pharmacokinetic (PK) study design of rupatadine for 2-5 year olds by using a population PK model developed with data from a study in 6-11 year olds. The design optimisation was driven by the need to avoid children's discomfort in the study. METHODS: PK data from 6-11 year olds with allergic rhinitis available from a previous study were used to construct a population PK model which we used in simulations to assess the dose to administer in a study in 2-5 year olds. In addition, an optimal design approach was used to determine the most appropriate number of sampling groups, sampling days, total samples and sampling times. RESULTS: A two-compartmental model with first-order absorption and elimination, with clearance dependent on weight adequately described the PK of rupatadine for 6-11 year olds. The dose selected for a trial in 2-5 year olds was 2.5 mg, as it provided a Cmax below the 3 ng/ml threshold. The optimal study design consisted of four groups of children (10 children each), a maximum sampling window of 2 hours in two clinic visits for drawing three samples on day 14 and one on day 28 coinciding with the final examination of the study. CONCLUSIONS: A PK study design was optimised in order to prioritise avoidance of discomfort for enrolled 2-5 year olds by taking only four blood samples from each child and minimising the length of hospital stays.
Asunto(s)
Antialérgicos/farmacocinética , Ciproheptadina/análogos & derivados , Rinitis Alérgica/tratamiento farmacológico , Algoritmos , Antialérgicos/administración & dosificación , Antialérgicos/sangre , Antialérgicos/uso terapéutico , Niño , Preescolar , Simulación por Computador , Ciproheptadina/administración & dosificación , Ciproheptadina/sangre , Ciproheptadina/farmacocinética , Ciproheptadina/uso terapéutico , Femenino , Humanos , Masculino , Modelos Biológicos , Proyectos de InvestigaciónRESUMEN
Allergy accounts to near 0.5% of all reported transfusion adverse events. The responsibility of blood components themselves and - therefore - of blood donors is still questioned. The European Community undertook a large international survey to address the consistency and homogeneity of medical selection of blood donors with regard to the risk of allergy, and especially of transferring allergy to recipients. This short report presents the salient points of the survey, stressing that there is inconsistency in addressing the allergy question within countries or systems, with paths of improvement.
Asunto(s)
Donantes de Sangre , Selección de Donante/normas , Hipersensibilidad/epidemiología , Reacción a la Transfusión/prevención & control , Antialérgicos/sangre , Hipersensibilidad a las Drogas/sangre , Hipersensibilidad a las Drogas/epidemiología , Europa (Continente)/epidemiología , Encuestas de Atención de la Salud , Política de Salud , Humanos , Hipersensibilidad/sangre , Hipersensibilidad/prevención & control , Encuestas y CuestionariosRESUMEN
This study describes a specific, precise, sensitive and accurate method for simultaneous determination of hydroxyzine, loratadine, terfenadine, rupatadine and their main active metabolites cetirizine, desloratadine and fexofenadine, in serum and urine using meclizine as an internal standard. Solid-phase extraction method for sample clean-up and preconcentration of analytes was carried out using Phenomenex Strata-X-C and Strata X polymeric cartridges. Chromatographic analysis was performed on a Phenomenex cyano (150 × 4.6 mm i.d., 5 µm) analytical column. A D-optimal mixture design methodology was used to evaluate the effect of changes in mobile phase compositions on dependent variables and optimization of the response of interest. The mixture design experiments were performed and results were analyzed. The region of ideal mobile phase composition consisting of acetonitrile-methanol-ammonium acetate buffer (40 mm; pH 3.8 adjusted with acetic acid): 18:36:46% v/v/v was identified by a graphical optimization technique using an overlay plot. While using this optimized condition all analytes were baseline resolved in <10 min. Solvent mixtures were delivered at 1.5 mL/min flow rate and analytes peaks were detected at 222 nm. The proposed bioanalytical method was validated according to US Food and Drug Administration guidelines. The proposed method was sensitive with detection limits of 0.06-0.15 µg/mL in serum and urine samples. Relative standard deviation for inter- and intra-day precision data was found to be <7%. The proposed method may find application in the determination of selected antihistaminic drugs in biological fluids.
Asunto(s)
Antialérgicos/sangre , Antialérgicos/orina , Cromatografía Líquida de Alta Presión/métodos , Antagonistas de los Receptores Histamínicos H1/sangre , Antagonistas de los Receptores Histamínicos H1/orina , Antialérgicos/metabolismo , Ciproheptadina/análogos & derivados , Ciproheptadina/sangre , Ciproheptadina/metabolismo , Ciproheptadina/orina , Antagonistas de los Receptores Histamínicos H1/metabolismo , Humanos , Hidroxizina/sangre , Hidroxizina/metabolismo , Hidroxizina/orina , Límite de Detección , Loratadina/sangre , Loratadina/metabolismo , Loratadina/orina , Extracción en Fase Sólida/métodos , Terfenadina/sangre , Terfenadina/metabolismo , Terfenadina/orinaRESUMEN
A multiple reaction monitoring (MRM), positive ion electrospray ionization, LC/MS/MS method is described for the quantification of cetirizine. The compound was isolated from human plasma by protein precipitation using acetonitrile. Cetirizine d4 was used as an internal standard. Chromatographic conditions were achieved using a C18 column and a combination of ammonium acetate, water, and methanol as the mobile phase. MRMs were: cetirizine, 389.26 â 165.16, 201.09; cetirizine d4, 393.09 â 165.15, 201.10. Calibration curves were constructed by plotting the peak area ratios of the calibrators' target MRM transition area to labeled internal standard target MRM transition area versus concentration.
Asunto(s)
Antialérgicos/sangre , Cetirizina/sangre , Cromatografía Líquida de Alta Presión/métodos , Antagonistas de los Receptores Histamínicos H1 no Sedantes/sangre , Espectrometría de Masas en Tándem/métodos , Monitoreo de Drogas/métodos , HumanosRESUMEN
The purpose was to improve the encapsulation efficiency of cetirizine hydrochloride (CTZ) microspheres as a model for water soluble drugs and control its release by applying response surface methodology. A 3(3) Box-Behnken design was used to determine the effect of drug/polymer ratio (X1), surfactant concentration (X2) and stirring speed (X3), on the mean particle size (Y1), percentage encapsulation efficiency (Y2) and cumulative percent drug released for 12 h (Y3). Emulsion solvent evaporation (ESE) technique was applied utilizing Eudragit RS100 as coating polymer and span 80 as surfactant. All formulations were evaluated for micromeritic properties and morphologically characterized by scanning electron microscopy (SEM). The relative bioavailability of the optimized microspheres was compared with CTZ marketed product after oral administration on healthy human volunteers using a double blind, randomized, cross-over design. The results revealed that the mean particle sizes of the microspheres ranged from 62 to 348 µm and the efficiency of entrapment ranged from 36.3% to 70.1%. The optimized CTZ microspheres exhibited a slow and controlled release over 12 h. The pharmacokinetic data of optimized CTZ microspheres showed prolonged tmax, decreased Cmax and AUC0-∞ value of 3309 ± 211 ng h/ml indicating improved relative bioavailability by 169.4% compared with marketed tablets.
Asunto(s)
Cetirizina/administración & dosificación , Cetirizina/sangre , Preparaciones de Acción Retardada/química , Antagonistas de los Receptores Histamínicos H1 no Sedantes/administración & dosificación , Antagonistas de los Receptores Histamínicos H1 no Sedantes/sangre , Resinas Acrílicas/química , Administración Oral , Adulto , Antialérgicos/administración & dosificación , Antialérgicos/sangre , Antialérgicos/química , Cetirizina/química , Estudios Cruzados , Método Doble Ciego , Hexosas/química , Antagonistas de los Receptores Histamínicos H1 no Sedantes/química , Humanos , Masculino , Solubilidad , Tensoactivos/química , Agua/química , Adulto JovenRESUMEN
PURPOSE: We examined the effect of a single apple juice intake on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese subjects. METHODS: In a randomized two phase, open-label crossover study, 14 subjects received 60 mg of racemic fexofenadine simultaneously with water or apple juice. For the uptake studies, oocytes expressing organic anion-transporting polypeptide 2B1 (OATP2B1) were incubated with 100 µM (R)- and (S)-fexofenadine in the presence or absence of 10 % apple juice. RESULTS: One-time ingestion of apple juice significantly decreased the area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine by 49 and 59 %, respectively, and prolonged the time to reach the maximum plasma concentration (t max) of both enantiomers (P < 0.001). Although apple juice greatly reduced the amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24) by 54 and 58 %, respectively, the renal clearances of both enantiomers were unchanged between the control and apple juice phases. For in vitro uptake studies, the uptake of both fexofenadine enantiomers into OATP2B1 complementary RNA (cRNA)-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine. In addition, apple juice significantly decreased the uptake of both enantiomers into OATP2B1 cRNA-injected oocytes. CONCLUSIONS: These results suggest that OATP2B1 plays an important role in the stereoselective pharmacokinetics of fexofenadine and that one-time apple juice ingestion probably inhibits intestinal OATP2B1-mediated transport of both enantiomers. In addition, this study demonstrates that the OATP2B1 inhibition effect does not require repeated ingestion or a large volume of apple juice.
Asunto(s)
Bebidas , Interacciones Alimento-Droga , Frutas , Malus , Transportadores de Anión Orgánico/metabolismo , Terfenadina/análogos & derivados , Adulto , Animales , Antialérgicos/sangre , Antialérgicos/química , Antialérgicos/farmacocinética , Antialérgicos/orina , Área Bajo la Curva , Estudios Cruzados , Ingestión de Alimentos , Femenino , Antagonistas de los Receptores Histamínicos H1 no Sedantes/sangre , Antagonistas de los Receptores Histamínicos H1 no Sedantes/química , Antagonistas de los Receptores Histamínicos H1 no Sedantes/farmacocinética , Antagonistas de los Receptores Histamínicos H1 no Sedantes/orina , Humanos , Absorción Intestinal , Masculino , Oocitos/metabolismo , Transportadores de Anión Orgánico/genética , ARN Complementario/genética , Estereoisomerismo , Terfenadina/sangre , Terfenadina/química , Terfenadina/farmacocinética , Terfenadina/orina , Xenopus laevis , Adulto JovenRESUMEN
The grapefruit juice (GFJ)-fexofenadine interaction involves inhibition of intestinal organic anion transporting polypeptide (OATP)-mediated uptake. Only naringin has been shown clinically to inhibit intestinal OATP; other constituents have not been evaluated. The effects of a modified GFJ devoid of furanocoumarins (~99%) and polymethoxyflavones (~90%) on fexofenadine disposition were compared to effects of the original juice. Extracts of both juices inhibited estrone 3-sulfate and fexofenadine uptake by similar extents in OATP-transfected cells (~50% and ~25%, respectively). Healthy volunteers (n = 18) were administered fexofenadine (120 mg) with water, GFJ, or modified GFJ (240 mL) by randomized, three-way crossover design. Compared to water, both juices decreased fexofenadine geometric mean AUC and C(max) by ~25% (P ≤ .008 and P ≤ .011, respectively), with no effect on terminal half-life (P = .11). Similar effects by both juices on fexofenadine pharmacokinetics indicate furanocoumarins and polymethoxyflavones are not major mediators of the GFJ-fexofenadine interaction.
Asunto(s)
Antialérgicos/farmacocinética , Bebidas , Citrus paradisi , Interacciones Alimento-Droga , Terfenadina/análogos & derivados , Adulto , Animales , Antialérgicos/sangre , Bebidas/análisis , Células COS , Chlorocebus aethiops , Cumarinas/análisis , Estudios Cruzados , Estrona/análogos & derivados , Estrona/metabolismo , Femenino , Flavonoides/análisis , Frutas , Células HEK293 , Humanos , Masculino , Persona de Mediana Edad , Transportadores de Anión Orgánico/antagonistas & inhibidores , Transportadores de Anión Orgánico/genética , Terfenadina/sangre , Terfenadina/farmacocinética , Adulto JovenRESUMEN
BACKGROUND: Current pharmacotherapy for allergic rhinitis (AR) does not totally ameliorate all symptoms for all patients. Residual symptoms could be due to nasal neuronal hyperresponsiveness caused by stimulation of the ion channel transient receptor potential vanilloid 1 (TRPV1). SB-705498 is a TRPV1 antagonist that has been developed in an intranasal formulation for treatment of AR. METHODS: This randomized, double-blind, 3-way incomplete block crossover study evaluated the effects of 8 days treatment with SB-705498 12 mg alone, SB-705498 12 mg plus fluticasone propionate 200 µg (FP), FP 200 µg alone or placebo on allergen-induced symptoms in 70 patients with AR. The primary endpoint was total nasal symptom score (TNSS), expressed as mean over 4 hours or maximum TNSS during allergen challenge in the Vienna Challenge Chamber on 8th day of treatment. RESULTS: At the end of treatment, there were no differences in allergen-induced mean TNSS between SB-705498 alone and placebo or between SB-705498 plus FP and FP alone. Treatment with FP and SB-705498 plus FP resulted in a significant decrease in TNSS vs. placebo. Mean (90% CI) treatment differences in TNSS over 0 - 4 hours were: SB-705498 - placebo: -0.2 (-0.9, 0.4); SB-705498 plus FP - FP: 0.7 (0.2, 1.2); FP - placebo: -2.9 (-3.4, -2.5); SB-705498 plus FP - placebo: -2.3 (-2.8, -1.8). SB-705498 had no impact on diary card symptoms, nasal airflow or Rhinoconjunctivitis Quality of Life Questionnaire scores. SB-705498 was well tolerated and pharmacokinetics exposure results supported the dosing regimen. CONCLUSION: SB-705498 12 mg for 8 days did not alleviate the allergen-induced symptoms of AR, or provide additional relief of symptoms when in combination with FP. Despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.
Asunto(s)
Antialérgicos/uso terapéutico , Pirrolidinas/uso terapéutico , Rinitis Alérgica Estacional/tratamiento farmacológico , Canales Catiónicos TRPV/antagonistas & inhibidores , Urea/análogos & derivados , Administración Intranasal , Adulto , Androstadienos/uso terapéutico , Antialérgicos/administración & dosificación , Antialérgicos/efectos adversos , Antialérgicos/sangre , Antialérgicos/farmacocinética , Austria , Estudios Cruzados , Método Doble Ciego , Quimioterapia Combinada , Femenino , Fluticasona , Humanos , Masculino , Pirrolidinas/administración & dosificación , Pirrolidinas/efectos adversos , Pirrolidinas/sangre , Pirrolidinas/farmacocinética , Rinitis Alérgica Estacional/diagnóstico , Rinitis Alérgica Estacional/metabolismo , Canales Catiónicos TRPV/metabolismo , Resultado del Tratamiento , Urea/administración & dosificación , Urea/efectos adversos , Urea/sangre , Urea/farmacocinética , Urea/uso terapéuticoRESUMEN
BACKGROUND: Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability. OBJECTIVES: The current trial was conducted to explore pharmacokinetics and pharmacodynamics of two nebulized inhalative epinephrine doses (4 mg and 8 mg in aqueous solution) using a mobile pocket inhaler relative to intramuscular administration (0.3 mg) and placebo. METHODS: This randomized, open-label, change-over pilot study involved eight young healthy men and women. Noncompartmental pharmacokinetic and pharmacodynamic parameters were calculated from epinephrine plasma concentrations and hemodynamic parameters. RESULTS: Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L). Maximal concentrations were reached within approximately 15 min for all active treatments. Epinephrine effects for inhalative administrations on heart rates were significantly higher than those for the intramuscular or placebo administration, while no excessive effects occurred. Pronounced overall variability prohibited a definite assessment of relative bioavailability between treatments. However, results indicated that epinephrine concentrations obtained following the 8 mg inhalative dose were not inferior to those after 0.3 mg i.m. CONCLUSIONS: A relevant fraction of moist inhalation epinephrine doses is absorbed and mediates systemic effects. This suggests that administration of epinephrine via a suitable pocket inhaler device may be beneficial in ambulatory emergency treatment of systemic hypersensitivity reactions. EudraCT number: 2010-021493-11.
Asunto(s)
Agonistas Adrenérgicos/administración & dosificación , Agonistas Adrenérgicos/farmacocinética , Antialérgicos/administración & dosificación , Antialérgicos/farmacocinética , Epinefrina/administración & dosificación , Epinefrina/farmacocinética , Nebulizadores y Vaporizadores , Absorción , Administración por Inhalación , Agonistas Adrenérgicos/efectos adversos , Agonistas Adrenérgicos/sangre , Adulto , Antialérgicos/efectos adversos , Antialérgicos/sangre , Área Bajo la Curva , Química Farmacéutica , Estudios Cruzados , Epinefrina/efectos adversos , Epinefrina/sangre , Diseño de Equipo , Femenino , Alemania , Hemodinámica/efectos de los fármacos , Humanos , Inyecciones Intramusculares , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Modelos Biológicos , Soluciones Farmacéuticas , Proyectos PilotoRESUMEN
The natural product (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolin-2-one (indolinone) was identified some years ago as a nanomolar inhibitor of FcÉRI-receptor dependent mast cell degranulation. To further explore the potential of the compound, we established an UPLC-MS/MS assay for dosage in rat plasma. The method was fully validated according to FDA Guidance for industry. Results of this validation and long term stability study demonstrate that the method in lithium heparinized rat plasma is specific, accurate, precise and capable of producing reliable results according to recommendations of international guidelines. The method was validated with a LLOQ of 30.0 ng/mL and an ULOQ of 3000 ng/mL. The response versus concentration data were fitted with a first order polynomial with 1/X(2) weighting. No matrix effect was observed when using three independent sources of rat plasma. The average extraction recovery was consistent over the investigated range. This validation in rat plasma demonstrated that indolinone was stable for 190 days when stored below -65 °C; for 4 days at 10 °C in the autosampler; for 4h at RT, and during three successive freeze/thaw cycles at -65 °C. Preliminary pharmacokinetic data were obtained in male Sprague-Dawley rats (2 mg/kg BW i.v.). Blood samples taken from 0 to 12 h after injection were collected, and data analyzed with WinNonlin. A short half-life (4.30±0.14 min) and a relatively high clearance (3.83±1.46 L/h/kg) were found.
Asunto(s)
Antialérgicos/sangre , Cromatografía Líquida de Alta Presión/métodos , Indoles/sangre , Animales , Antialérgicos/química , Antialérgicos/farmacocinética , Estabilidad de Medicamentos , Indoles/química , Indoles/farmacocinética , Isomerismo , Límite de Detección , Masculino , Ratas , Ratas Sprague-Dawley , Análisis de Regresión , Reproducibilidad de los Resultados , Espectrometría de Masas en TándemRESUMEN
The purpose of the present study is to examine the long-lasting inhibition of intestinal organic anion transporting polypeptides (Oatps) by cyclosporin A (CsA) in rats using fexofenadine (FEX) as a probe drug. We examined the pharmacokinetics of FEX after its intravenous or oral administration to rats at 3 or 24 h after the oral administration of CsA. When FEX was administered at 3 h after the administration of CsA, its plasma concentration increased regardless of whether it was administered intravenously or orally. When FEX was intravenously administered at 24 h after the oral administration of CsA, its plasma concentration was increased; however, that observed after its oral administration was not significantly different from the vehicle-treated control. When FEX was administered at 3 h after the administration of CsA, the hepatic availability (F(h)) and the fraction absorbed in the intestine as an unchanged form (F(a)·F(g)) of FEX were increased, resulting in increased bioavailability (=F(a)·F(g)·F(h)). At 24 h after the administration of CsA, the F(h) of FEX was increased, whereas its bioavailability was decreased, suggesting that its F(a)·F(g) was decreased because of the long-lasting inhibition. In conclusion, CsA has long-lasting inhibitory effects on Oatps in the rat intestine as well as in the liver.
Asunto(s)
Antialérgicos/farmacocinética , Antifúngicos/farmacología , Ciclosporina/farmacología , Absorción Intestinal/efectos de los fármacos , Transportadores de Anión Orgánico/antagonistas & inhibidores , Terfenadina/análogos & derivados , Administración Oral , Animales , Antialérgicos/administración & dosificación , Antialérgicos/sangre , Antifúngicos/administración & dosificación , Antifúngicos/sangre , Ciclosporina/administración & dosificación , Ciclosporina/sangre , Regulación de la Expresión Génica/efectos de los fármacos , Inyecciones Intravenosas , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Transportadores de Anión Orgánico/genética , ARN Mensajero/genética , Ratas , Ratas Sprague-Dawley , Terfenadina/administración & dosificación , Terfenadina/sangre , Terfenadina/farmacocinéticaRESUMEN
The effect of bilastine on cardiac repolarization was studied in 30 healthy participants during a multiple-dose, triple-dummy, crossover, thorough QT study that included 5 arms: placebo, active control (400 mg moxifloxacin), bilastine at therapeutic and supratherapeutic doses (20 mg and 100 mg once daily, respectively), and bilastine 20 mg administered with ketoconazole 400 mg. Time-matched, triplicate electrocardiograms (ECGs) were recorded with 13 time points extracted predose and 16 extracted over 72 hours post day 4 dosing. Four QT/RR corrections were implemented: QTcB; QTcF; a linear individual correction (QTcNi), the primary correction; and a nonlinear one (QTcNnl). Moxifloxacin was associated with a significant increase in QTcNi at all time points between 1 and 12 hours, inclusively. Bilastine administration at 20 mg and 100 mg had no clinically significant impact on QTc (maximum increase in QTcNi, 5.02 ms; upper confidence limit [UCL] of the 1-sided, 95% confidence interval, 7.87 ms). Concomitant administration of ketoconazole and bilastine 20 mg induced a clinically relevant increase in QTc (maximum increase in QTcNi, 9.3 ms; UCL, 12.16 ms). This result was most likely related to the cardiac effect of ketoconazole because for all time points, bilastine plasma concentrations were lower than those observed following the supratherapeutic dose.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Antialérgicos/efectos adversos , Bencimidazoles/efectos adversos , Electrocardiografía/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H1 no Sedantes/efectos adversos , Cetoconazol/efectos adversos , Piperidinas/efectos adversos , Adulto , Antialérgicos/administración & dosificación , Antialérgicos/sangre , Antialérgicos/farmacocinética , Bencimidazoles/administración & dosificación , Bencimidazoles/sangre , Bencimidazoles/farmacocinética , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Interacciones Farmacológicas , Femenino , Semivida , Antagonistas de los Receptores Histamínicos H1 no Sedantes/administración & dosificación , Antagonistas de los Receptores Histamínicos H1 no Sedantes/sangre , Antagonistas de los Receptores Histamínicos H1 no Sedantes/farmacocinética , Humanos , Masculino , Tasa de Depuración Metabólica/efectos de los fármacos , Piperidinas/administración & dosificación , Piperidinas/sangre , Piperidinas/farmacocinética , Adulto JovenRESUMEN
OBJECTIVE AND DESIGN: Comparison of bilastine and cetirizine in inhibiting skin wheal and flare responses over 24 h. SUBJECTS: Twenty-one healthy male volunteers (aged 19-44 years). TREATMENT AND METHODS: Volunteers were randomised to receive single oral doses of 20 or 50 mg bilastine, 10 mg cetirizine or placebo before provocation of wheal and flare responses to 100 mg/ml histamine by skin prick 1.5, 4, 8, 12 and 24 h later. RESULTS: There were no significant differences between overall inhibitions of wheal or flare by 20 mg bilastine and 10 mg cetirizine. Bilastine was faster in onset than cetirizine, inhibitions of wheal and flare at 1.5 h being 89 ± 3 versus 44 ± 14% (P = 0.011) and 85 ± 4 versus 45 ± 14% (P = 0.016), respectively (Student's t test). At 1.5 h, both wheals and flares were inhibited by >70% in 11/12 volunteers taking bilastine and 3/11 taking cetirizine (P = 0.003, Fisher's exact test). There were no significant differences between the drugs at later times. Bilastine 50 mg had a longer duration of action than bilastine 20 mg. CONCLUSIONS: Both 20 mg bilastine and 10 mg cetirizine are effective and of long duration in reducing histamine-induced wheal and flare responses, the major difference between the two drugs being the more rapid onset of action of bilastine.